CLDX
Celldex Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.64 / 10
Netural
Sentiment is neutral (4.64) while fund‑flow scores 7.63, indicating good liquidity with positive medium and large inflows but negative overall and block trends. Analyst consensus is split: 50% Strong Buy, 50% Neutral, with mixed historical performance. Caution advised.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-26
InstitutionStifel
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for CLDX?
- CLDX holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.64/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
